MAPK9 and colonic neoplasm: MAPK9 is a first neighbour of a colon cancer-related protein, β-catenin, and inhibition of MAPK9 was found to down-regulate β-catenin.63 Supporting the probably beneficial affect of midostaurin, a previous in vitro study found that midostaurin sensitized colon cancer cells against chemotherapeutic agents.64